About Femasys
Femasys is a company based in Atlanta (United States) founded in 2004. It operates as a Direct-to-Consumer (D2C), and HealthTech. Femasys has raised $69.22 million across 17 funding rounds from investors including Salem Partners, PharmaCyte Biotech and Legacy Capital Advisors, LLC. The company has 71 employees as of December 31, 2024. Femasys offers products and services including FemaSeed, FemVue, FemBloc, and FemCerv. Femasys operates in a competitive market with competitors including Daré Bioscience, Aindra, MTM Laboratories, Teal Health and Aspivix, among others.
- Headquarter Atlanta, United States
- Employees 71 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Femasys Inc.
-
Annual Revenue
$1.63 M51.97as on Dec 31, 2024
-
Net Profit
$-18.82 M-32.07as on Dec 31, 2024
-
EBITDA
$-16.91 M-24.36as on Dec 31, 2024
-
Total Equity Funding
$69.22 M (USD)
in 17 rounds
-
Latest Funding Round
$8.03 M (USD), Post-IPO
Nov 07, 2025
-
Investors
Salem Partners
& 2 more
-
Employee Count
71
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Femasys
Femasys is a publicly listed company on the NASDAQ with ticker symbol FEMY in USA, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Femasys
Femasys offers a comprehensive portfolio of products and services, including FemaSeed, FemVue, FemBloc, and FemCerv. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative solution for infertility treatment in women provided.
Diagnostic tool for infertility assessment in women offered.
Permanent birth control solution for women is developed.
Tool for cervical cancer diagnosis in women provided.
Unlock access to complete
Funding Insights of Femasys
Femasys has successfully raised a total of $69.22M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $8.03 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 17
- Last Round Post-IPO — $8.0M
-
First Round
First Round
(01 Sep 2005)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Post-IPO - Femasys | Valuation |
investors |
|
| Jun, 2025 | Amount | Post-IPO - Femasys | Valuation |
investors |
|
| Nov, 2023 | Amount | Post-IPO - Femasys | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Femasys
Femasys has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Salem Partners, PharmaCyte Biotech and Legacy Capital Advisors, LLC. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of targeted therapeutics for cancer and diabetes
|
Founded Year | Domain | Location | |
|
Regional investment bank
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Femasys
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Femasys
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Femasys Comparisons
Competitors of Femasys
Femasys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Aindra, MTM Laboratories, Teal Health and Aspivix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| domain | founded_year | HQ Location |
AI-powered systems for cervical cancer detection are provided.
|
|
| domain | founded_year | HQ Location |
In vitro diagnostics for early cervical cancer detection are manufactured.
|
|
| domain | founded_year | HQ Location |
Cervical cancer screening kits are provided by Teal Health.
|
|
| domain | founded_year | HQ Location |
A next-generation suction-based cervical device for gynecology is provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Femasys
Frequently Asked Questions about Femasys
When was Femasys founded?
Femasys was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Where is Femasys located?
Femasys is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Is Femasys a funded company?
Femasys is a funded company, having raised a total of $69.22M across 17 funding rounds to date. The company's 1st funding round was a Post-IPO of $6.85M, raised on Sep 01, 2005.
How many employees does Femasys have?
As of Dec 31, 2024, the latest employee count at Femasys is 71.
What is the annual revenue of Femasys?
Annual revenue of Femasys is $1.63M as on Dec 31, 2024.
What does Femasys do?
Femasys is engaged in creating next-generation medical devices and solutions targeting underserved areas in womens health. The company is dedicated to addressing critical needs in infertility, birth control, and cancer diagnosis. Products such as FemaSeed, FemVue, and FemBloc are developed to provide transformative healthcare options. Safety and high standards of care are prioritized in all offerings. The focus is maintained on global unmet needs within the healthcare sector for women.
Who are the top competitors of Femasys?
Femasys's top competitors include Daré Bioscience, Aindra and Teal Health.
What products or services does Femasys offer?
Femasys offers FemaSeed, FemVue, FemBloc, and FemCerv.
Is Femasys publicly traded?
Yes, Femasys is publicly traded on NASDAQ under the ticker symbol FEMY.
Who are Femasys's investors?
Femasys has 3 investors. Key investors include Salem Partners, PharmaCyte Biotech, and Legacy Capital Advisors, LLC.
What is Femasys's ticker symbol?
The ticker symbol of Femasys is FEMY on NASDAQ.